Dechra Pharmaceuticals PLC (LSE:DPH) acquired Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc. for $64.5 million on January 10, 2022. The consideration include an initial payment of $19.0 million, there are subsequent milestone payments totaling $45.5 million due on the achievement of various approval and sales milestones for the product in the USA, UK, EU, Brazil, Australia, Japan and Canada. Royalties are also payable as part of this transaction. Under the terms of the agreement, Dechra will acquire the global product rights and a first right of refusal for other species along with the trademark (Laverdia). Dechra will acquire the worldwide marketing rights, the rights to the intellectual property, the marketing authorizations (when granted) and associated regulatory documentation, supply contracts with third parties in relation to the raw material and manufacture of the finished product. No other assets are being transferred to Dechra.

Dechra Pharmaceuticals PLC (LSE:DPH) completed the acquisition of Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc. on January 10, 2022.